{
  "title": "Paper_606",
  "abstract": "pmc Biomed Res Int Biomed Res Int 2029 bmri BMRI BioMed Research International 2314-6133 2314-6141 Wiley PMC12459310 PMC12459310.1 12459310 12459310 41031259 10.1155/bmri/9170020 BMRI9170020 1 Research Article Article Mechanistic Exploration of Carpobrotus edulis Lukman Halimat Yusuf https://orcid.org/0000-0001-9873-4915  1 Rampadarath Athika https://orcid.org/0000-0002-4874-6376  1 Amoo Stephen https://orcid.org/0000-0003-0009-5436  2  3 Sabiu Saheed https://orcid.org/0000-0001-7209-9220  1 sabius@dut.ac.za Banerjee Baisakhi bbanerjee@wiley.com   1 Department of Biotechnology and Food Science Durban University of Technology Durban South Africa dut.ac.za   2 Agricultural Research Council-Vegetables Industrial and Medicinal Plants Pretoria South Africa   3 Unit for Environmental Science and Management North-West University Potchefstroom South Africa nwu.ac.za 24 9 2025 2025 2025 479482 9170020 03 8 2025 25 7 2024 22 8 2025 24 09 2025 30 09 2025 01 10 2025 Copyright © 2025 Halimat Yusuf Lukman et al. BioMed Research International published by John Wiley & Sons Ltd. 2025 https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ Despite the reported antidiabetic potential of Carpobrotus edulis C. edulis C. edulis C. edulis C. edulis C. edulis C. edulis C. edulis C. edulis Keywords Carpobrotus edulis molecular dynamics simulation network pharmacology signaling pathway Type 2 diabetes mellitus National Research Foundation 10.13039/501100001321 SRUG2204193723 Technology Innovative Agency South African Medical Research Council 10.13039/501100001322 pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes source-schema-version-number 2.0 cover-date 2025 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:24.09.2025  Lukman Halimat Yusuf Rampadarath Athika Amoo Stephen Sabiu Saheed Mechanistic Exploration of Carpobrotus edulis BioMed Research International 2025 9170020 2025 10.1155/bmri/9170020  Academic Editor: 1. Introduction Network pharmacology (NP) is a computational tool that systematically elucidates the mechanism of action of bioactive compounds in the management and/or treatment of disorders using the multitarget and multicomponent approach [ 1 2 3 4 5 7 Khaya grandifoliola 8 8 9 ′ 9 The annual death record and projected increasing prevalence of diabetes [ 10 11 12 13 14 15 20 Carpobrotus edulis  C. edulis 21 23 C. edulis 24 25 C. edulis 26 C. edulis 27 C. edulis 28 C. edulis C. edulis Despite the commendable reports on the antidiabetic activity of C. edulis C. edulis 2. Materials and Methods 2.1. Data Mining for C. edulis Twenty‐four C. edulis 28 https://pubmed.ncbi.nlm.nih.gov/?term=Carpobrotus%2520edulis%2520chemicals http://swissadme.ch/index.php 29 2.2. Acquisition and Preparation of C. edulis The target genes of C. edulis https://pubchem.ncbi.nlm.nih.gov/ http://sea.bkslab.org/ http://www.swisstargetprediction.ch/ https://www.genecards.org https://www.disgenet.org/search 30 https://bioinfogp.cnb.csic.es/tools/venny/ C. edulis 2.3. Creation of Intersecting Target Network The protein–protein interaction (PPI) ( Homo sapiens C. edulis https://string-db.org/ 31 C. edulis 32 1 33 (1) Deg V = N V , V N v 2.4. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) Analyses of the Overlapping Targets The official gene symbol identifier for Homo sapiens https://david.ncifcrf.gov/tools.jsp 15 16 Q p https://www.bioinformatics.com.cn/ 2.5. Molecular Docking and MD Simulation The 3D structures of the most enriched genes ([estrogen receptor 1 [ESR1] [PDB ID:1X7R] and estrogen receptor 2 [ESR2] [PDB ID:1X7J]) identified in the most significant T2DM pathway were obtained from the RSCB Protein Data Bank ( https://www.rcsb.org/ 34 C. edulis https://pubchem.ncbi.nlm.nih.gov/ 35 The optimized metabolites were subjected to docking using the Autodock Vina Plugin on Chimera into ESR1 and ESR2 binding pockets with a grid box defined with a space of 1 Å, centers (X: 16.595, Y: 31.9366, and Z: 12.4095) for ESR1 and (X: 31.3211, Y: 36.7317, and Z: 40.704) for ESR2 [ 36 1 37 38 39 40 Figure 1 Superimposition of (a) ESR1 with the best docked metabolite “epicatechin” (purple) and tamoxifen (green) on native ligand “genistein” (yellow) and (b) ESR2 with the best docked metabolite “ellagic acid” (purple) and “tamoxifen: (green) on native ligand “genistein” (yellow). (a) (b) 3. Results 3.1. Drug‐Likeness Filtering of C. edulis Of the 23 metabolites of C. edulis 1 1 Table 1 Drug‐likeness properties of C. edulis  Metabolites  Pass Lipinski’s filter  Violations (V) 1,3‐Dicaffeoylquinic acid No 3 V: MW > 500, HBD > 10 Cacticin No 2 V: HBD > 10, HBA > 5 Caffeic acid Yes — Catechin Yes — Catechin‐ O No 2 V: HBD > 10, HBA > 5 Chlorogenic acid Yes — Ellagic acid Yes — Epicatechin Yes — Ferulic acid Yes — Gallic acid Yes — Hyperoside No 2 V: HBD > 10, HBA > 5 Isoquercetin No 2 V: HBD > 10, HBA > 5 Isorhamnetin‐3‐O‐rutinoside No 3 V: MW > 500, HBD > 10, HBA > 5 Myricetin Yes — Luteolin 7‐O‐beta‐D‐glucoside No 2 V: HBD > 10, HBA > 5 Neohesperidin No 3 V: MW > 500, HBD > 10, HBA > 5 Phloretin‐glucoside No HBD > 10, HBA > 5 Procyanidin No 3 V: MW > 500, HBD > 10, HBA > 5 Protocatechuic acid‐ O Yes — Quinic acid Yes — Rutin No 3 V: MW > 500, HBD > 10, HBA > 5 Sinapic acid Yes — Syringetin‐3‐O‐rutinoside No 3 V: MW > 500, HBD > 10, HBA > 5 Abbreviations: HBA, number of hydrogen bond acceptor; HBD, number of hydrogen bond donor; MW, molecular weight. 3.2. Potential Overlapping Targets Between T2DM Targets and C. edulis A total of 59 (9.4%) common genes were observed between the STP (238) and SEA (449) genes for the 11 metabolites (Figure 2a 2b C. edulis 2c Figure 2 Common genes between (a) STP and SEA genes retrieved for C. edulis C. edulis (a) (b) (c) 3.3. PPI of the Overlapping Genes in C. edulis The PPI of the overlapping 34 genes associated with C. edulis 3 3 Figure 3 PPI of the 34 common genes of T2DM and C. edulis 3.4. GO and KEGG Pathway Enrichment Analyses of the 34 Overlapping Genes The Top 10 BP, MF, and CC of the 34 overlapping genes are shown in Figure 4 p −8 C. edulis p −8 p −6 C. edulis Figure 4 Bubble map of the top 10 GO annotations for the 34 common targets. The KEGG pathway enrichment analysis for the Top 10 signaling pathways identified in the T2DM– C. edulis 5 p 2 2 Figure 5 KEGG bubble map enrichment analysis of the Top 10 signaling pathways associated with the 34 common genes. Table 2 The signaling pathways and target genes related to C. edulis  Signaling pathway  False discovery rate  Genes Endocrine resistance 2.48 × 10 −13 MMP2, IGF1R, ERBB2, EGFR, BRAF, ESR2, MMP9, SRC, ESR1, and AKT1 EGFR tyrosine kinase inhibitor resistance 1.17 × 10 −10 IGF1R, ERBB2, EGFR, BRAF, MET, GSK3B, SRC, and AKT1 Focal adhesion 2.14 × 10 −9 IGF1R, ERBB2, EGFR, BRAF, MET, GSK3B, MYLK, SRC, and AKT1 Fox O 2.16 × 10 −9 EP300, CDK2, IGF1R, EGFR, BRAF, PLK1, INSR, and AKT1 Breast cancer 5.36 × 10 −9 IGF1R, ERBB2, EGFR, BRAF, GSK3B, ESR2, ESR1, and AKT1 Hepatocellular carcinoma 1.04 × 10 −9 IGF1R, EGFR, BRAF, TERT, MET, NQO1, GSK3B, and AKT1 HIF‐1 2.15 × 10 −8 NFKB1, EP300, IGF1R, ERBB2, EGFR, INSR, and AKT1 Prolactin 6.95 × 10 −8 NFKB1, GSK3B, ESR2, SRC, ESR1, and AKT1 Relaxin 6.95 × 10 −8 MMP2, NFKB1, EGFR, MMP1, MMP9, SRC, and AKT1 Non–small cell lung cancer 6.95 × 10 −8 ERBB2, EGFR, BRAF, MET, RARB, and AKT1 Estrogen 7.38 × 10 −8 MMP2, EGFR, ESR2, MMP9, SRC, ESR1, and AKT1 PI3K‐Akt 1.37 × 10 −7 NFKB1, CDK2, IGF1R, ERBB2, EGFR, INSR, MET, GSK3B, and AKT1 ErbB 1.59 × 10 −7 ERBB2, EGFR, BRAF, GSK3B, SRC, and AKT1 MAPK 5.09 × 10 −7 NFKB1, IGF1R, ERBB2, EGFR, BRAF, INSR, MET, and AKT1 Rap1 9.12 × 10 −7 IGF1R, EGFR, BRAF, INSR, MET, SRC, and AKT1 Fluid shear stress and atherosclerosis 1.60 × 10 −6 MMP2, NFKB1, NQO1, MMP9, SRC, and AKT1 Pancreatic cancer 2.88 × 10 −6 NFKB1, ERBB2, EGFR, BRAF, and AKT1 Thyroid hormone 2.43 EP300, GSK3B, SRC, ESR1, and AKT1 Alzheimer disease 2.54 × 10 −5 NFKB1, NOX4, BRAF, INSR, BACE1, GSK3B, and AKT1 Ras 2.68 × 10 −5 NFKB1, IGF1R, EGFR, INSR, MET, and AKT1 Renal cell carcinoma 6.30e × 10 −5 EP300, BRAF, MET, and AKT1 mTOR 6.48 × 10 −5 IGF1R, BRAF, INSR, GSK3B, and AKT1 Chemokine 1.5 × 10 −4 NFKB1, BRAF, GSK3B, SRC, and AKT1 IL‐17 1.7 × 10 −4 NFKB1, MMP1, GSK3B, and MMP9 AGE‐RAGE in diabetic complications 2.1 × 10 −4 MMP2, NFKB1, NOX4, and AKT1 cAMP 2.3 × 10 −4 NFKB1, EP300, BRAF, HCAR2, and AKT1 Insulin resistance 2.7 × 10 −4 NFKB1, INSR, GSK3B, and AKT1 Insulin 5.6 × 10 −4 BRAF, INSR, GSK3B, and AKT1 Nonalcoholic fatty liver disease 8.1 × 10 −4 NFKB1, INSR, GSK3B, and AKT1 B cell receptor 1.9 × 10 −3 NFKB1, GSK3B, and AKT1 GnRH 2.7 × 10 −3 MMP2, EGFR, and SRC C‐type lectin receptor 3.8 × 10 −3 NFKB1, SRC, and AKT1 T cell receptor 3.8 × 10 −3 NFKB1, GSK3B, and AKT1 TNF 4.9 × 10 −3 NFKB1, MMP9, and AKT1 Growth hormone synthesis, secretion, and action 5.6 × 10 −3 EP300, GSK3B, and AKT1 AMPK 5.8 × 10 −3 IGF1R, INSR, and AKT1 Phospholipase D 9.5 × 10 −3 EGFR, INSR, and AKT1 Oxytocin 9.8 × 10 −3 EGFR, MYLK, and SRC JAK‐STAT 1.16 × 10 −2 EP300, EGFR, and AKT1 cGMP‐PKG 1.19 × 10 −2 INSR, MYLK, and AKT1 Axon guidance 1.47 × 10 −2 MET, GSK3B, and SRC Regulation of lipolysis in adipocytes 1.66 × 10 −2 INSR and AKT1 VEGF 1.81 × 10 −2 SRC and AKT1 Long‐term depression 1.87 × 10 −2 IGF1R and BRAF Adipocytokine 2.43 × 10 −2 NFKB1 and AKT1 Glucagon 4.62 × 10 −2 EP300 and AKT1 Parathyroid hormone synthesis, secretion, and action 4.70 × 10 −2 EGFR and BRAF 3.5. Network Interaction of Endocrine Resistance Pathway, Genes, and C. edulis The PCT interaction of the most enriched pathway, its genes, and C. edulis 6a 6b C. edulis 7 7a 7b C. edulis Figure 6 (a) PCT network of C. edulis (a) (b) Figure 7 Network construction of C. edulis (a) (b) 3.6. Docking Interaction of C. edulis The docking scores and 2D interaction of C. edulis 2 3 3 3 C. edulis 3 3 Table 3 Docking scores and energy components of Top 4 metabolites of C. edulis  Complexes  kcal/mol  Docking score  Δ E  v d W  Δ E  e l e c  Δ G  g a s  Δ G  s o l v  Δ G  b i n d  ESR1 Catechin −9.1 −34.09 ± 3.48 −55.80 ± 5.57 −89.89 ± 4.90 40.22 ± 3.53 −49.67 ± 3.03 Ellagic acid −9.4 −38.02 ± 2.67 −19.40 ± 6.72 −57.41 ± 7.12 24.44 ± 2.20 −32.97 ± 3.58 Epicatechin −8.7 −37.41 ± 3.08 −40.91 ± 6.65 −78.33 ± 6.36 35.36 ± 3.21 −42.97 ± 4.00 Protocatechuic acid 3‐glucoside −7.5 −41.07 ± 2.85 −26.59 ± 5.84 −67.66 ± 5.12 27.68 ± 3.88 −39.98 ± 3.58 Metformin −5.1 −18.58 ± 2.30 −162.42 ± 17.21 −181.00 ± 17.53 166.29 ± 15.21 −14.21 ± 4.11 Tamoxifen −6.8 −16.85 ± 7.45 −78.43 ± 20.50 −95.23 ± 23.24 82.89 ± 20.67 −12.34 ± 6.02  ESR2 Catechin −8.5 −36.67 ± 3.58 −47.07 ± 9.19 −83.75 ± 7.82 31.33 ± 2.75 −52.42 ± 5.82 Ellagic acid −8.5 −23.35 ± 3.65 −46.68 ± 9.8 −70.04 ± 10.19 36.83 ± 5.02 −33.21 ± 5.74 Epicatechin −8.8 −35.35 ± 3.53 −57.49 ± 6.83 −92.83 ± 5.67 38.24 ± 3.40 −58.59 ± 3.66 Myricetin −8.4 −37.77 ± 3.57 −51.75 ± 4.91 −89.52 ± 4.14 37.56 ± 2.10 −51.96 ± 3.19 Metformin −5.1 −20.09 ± 2.48 −95.55 ± 13.70 −115.64 ± 13.51 94.99 ± 12.32 −20.65 ± 5.50 Tamoxifen −5.9 −55.49 ± 2.95 −103.71 ± 15.05 −159.20 ± 14.70 111.28 ± 13.29 −47.92 ± 3.36 Abbreviations: Δ E elec Δ E gas Δ E  V d W Δ G bind Δ G  s o l v 3.7. Postdynamic Trajectories of Top 4 C. edulis The postdynamic trajectories of the Top 4 C. edulis 8 9 4 4 4 4 4 Figure 8 Comparative postdynamic data showing (a) RMSD, (b) RMSF, (c) RoG, (d) SASA, and (e) number of intramolecular H‐bond plots of catechin, ellagic acid, epicatechin, and protocatechuic acid 3‐glucoside of C. edulis (a) (b) (c) (d) (e) Figure 9 Comparative postdynamic data showing (a) RMSD, (b) RMSF, (c) RoG, (d) SASA, and (e) number of intramolecular H‐bond plots of catechin, ellagic acid, epicatechin, and myricetin of C. (a) (b) (c) (d) (e) Table 4 Post‐MD simulation and hydrogen bond parameters of Top 4 metabolites of C. edulis  Complexes  RMSD (Å)  RMSF (Å)  RoG (Å)  SASA (Å)  Number of H-bonds  ESR1 Apo‐ESR1 1.84 ± 0.23 1.27 ± 0.62 18.20 ± 0.14 12803.75 ± 310.24 108.72 ± 7.31 Catechin 1.63 ± 0.19 1.24 ± 0.65 18.18 ± 0.07 12589.51 ± 261.55 115.07 ± 7.57 Ellagic acid 1.66 ± 0.27 1.18 ± 0.45 18.21 ± 0.07 12752.51 ± 216.55 111.21 ± 7.82 Epicatechin 1.72 ± 0.19 1.20 ± 0.50 18.04 ± 0.09 12495.50 ± 287.17 110.90 ± 7.21 Protocatechuic acid 3‐glucoside 1.66 ± 0.23 1.20 ± 0.66 18.29 ± 0.11 12379.48 ± 252.95 114.16 ± 7.27 Metformin 2.09 ± 0.31 1.35 ± 0.72 18.31 ± 0.08 13079.40 ± 341.62 109.38 ± 7.65 Tamoxifen 2.02 ± 0.23 1.33 ± 1.66 18.31 ± 0.15 13096.03 ± 275.66 111.17 ± 7.61  ESR2 Apo‐ESR2 1.68 ± 0.17 1.28 ± 0.5 17.95 ± 0.07 12298.32 ± 244.32 106.62 ± 7.73 Catechin 1.65 ± 0.18 1.22 ± 0.62 18.18 ± 0.07 12594.75 ± 325.12 115.23 ± 7.56 Ellagic acid 1.69 ± 0.26 1.16 ± 0.45 18.21 ± 0.07 12748.65 ± 262.79 111.26 ± 7.86 Epicatechin 1.58 ± 0.18 1.20 ± 0.52 18.03 ± 0.07 11908.18 ± 243.28 108.30 ± 7.47 Myricetin 1.53 ± 0.12 1.06 ± 0.40 17.94 ± 0.06 11609.05 ± 211.58 114.80 ± 7.51 Metformin 1.71 ± 0.25 1.40 ± 0.54 17.97 ± 0.09 12191.40 ± 300.38 107.43 ± 7.38 Tamoxifen 1.69 ± O.12 1.07 ± 0.40 17.98 ± 0.07 12246.60 ± 248.65 104.74 ± 7.17 Abbreviations: RMSD, root mean square deviation; RMSF, root mean square fluctuation; RoG, radius of gyration; SASA, solvent accessible surface area. For ESR2, all the systems equilibrated at the 0 ns and were stable throughout the 100 ns simulation (Figure 9a 4 9b 4 9c 4 9d 4 C. edulis 9e 4 3.8. Post‐MD Simulation Interaction Plots of the Top 4 Metabolites of C. edulis The 2D interaction plots of C. edulis 10 11 10a 10b 10c 10d 10e 10f Figure 10 2D postdynamic interaction of ESR2 with (a) catechin, (b) ellagic acid, (c) epicatechin, (d) myricetin, (e) metformin, and (f) tamoxifen at 0, 50, and 100 ns simulation. (a) (b) (c) (d) (e) (f) Figure 11 2D postdynamic interaction of ESR2 with (a) catechin, (b) ellagic acid, (c) epicatechin, (d) myricetin, (e) metformin, and (f) tamoxifen at 0, 50, and 100 ns simulation. (a) (b) (c) (d) (e) (f) For ESR2, 21 interactions were observed between catechin and ESR2 at 0 ns with four H‐bonds (Ala302, Glu305, Arg346, and Gly472) while only 19 interacting bonds with two H‐bonds (Glu41 and Gly209) were observed at the end of the 100 ns. The ellagic–ESR2 complex had 19 interactions, including two H‐bonds (Gly472 and Thr299) at 0 ns, while 17 interactions with three H‐bonds (Hie212, Gly209, and Met76) existed at the 100 ns period (Figure 11b 11c 11d 10e 10f 4. Discussion Medicinal plants contain a large reservoir of metabolites with therapeutic and nutritional values [ 41 42 43 44 C. edulis C. edulis 45 C. edulis 46 C. edulis C. edulis The GO analyzes the functional processes underlying molecular mechanisms of metabolites and targets [ 47 β 48 C. edulis 49 C. edulis The endocrine resistance pathway is implicated in resistance during endocrine therapy; therefore, it is necessary to explore the genes responsible for this resistance during the development of targeted drugs [ 50 β 51 52 C. edulis C. edulis 53 54 55 56 57 C. edulis NP is usually supported with MD simulation, as the latter helps to predict metabolites and targeted genes interaction for improved targeted drug development [ 58 59 60 C. edulis C. edulis The degree of interaction relative to flexibility, stability, and active site amino acid residues is obtained from the MD study. The RMSD determines the extent of a complex’s stability by measuring the fluctuation pattern of complexes, with more converged complexes depicting stability [ 61 8 The RMSF can be used to determine the fluctuations occurring at the protein active site when a ligand/compound binds; the higher the flexibility of amino acids, the lower the stability of the complex [ 62 C. edulis C. edulis 63 Δ G bind C. edulis 64 Δ G bind C. edulis Δ G bind The intermolecular interaction between ligand and protein depicts complex stability, and this can be predicted by the H‐bonds in the complex [ 65 C. edulis C. edulis C. edulis 66 C. edulis Δ G bind Δ G bind Insulin is an endocrine hormone responsible for the regulation of blood glucose [ 67 68 69 70 71 72 12 C. edulis Figure 12 Enriched genes (green) in the endocrine resistance signaling pathway implicated with C. edulis 5. Conclusion The metabolites of C. edulis C. edulis C. edulis C. edulis C. edulis Conflicts of Interest The authors declare no conflicts of interest. Author Contributions Halimat Yusuf Lukman: investigation, formal analysis, data curation, writing—original draft preparation, and writing—reviewing and editing. Athika Rampadarath: data curation, formal analysis, methodology, and investigation. Stephen Amoo: supervision and writing—reviewing and editing. Saheed Sabiu: conceptualization, methodology, project administration, supervision, and writing—reviewing and editing. Funding This study was funded by the South African Medical Research Council (SAMRC) (SRUG2204193723), the Technology Innovative Agency, and the National Research Foundation’s Competitive Programme for Rated Researchers Support (SRUG2204193723). Supporting information  Supporting Information C. edulis C. edulis Acknowledgments This study is funded by the South African Medical Research Council (SAMRC) under a Self‐Initiated Research Grant, the Technology Innovative Agency, and National Research Foundation’s Competitive Programme for Rated Researchers Support (SRUG2204193723) awarded to Saheed Sabiu. The authors wish to acknowledge the Directorate of Research and Postgraduate Support, Durban University of Technology, and Centre for High Performance Computing (CHPC), Cape Town, South Africa, for the provision of computing software and modules used in this study. Data Availability Statement The data presented in this study are available in the article. 1 Noor F. Tahir ul Qamar M. Ashfaq U. A. Albutti A. Alwashmi A. S. S. Aljasir M. A. Network Pharmacology Approach for Medicinal Plants: Review and Assessment Pharmaceuticals 2022 15 10.3390/ph15050572 PMC9143318 35631398 2 Casas A. I. Hassan A. A. Larsen S. J. Gomez Rangel V. Elbatreek M. Kleikers P. W. Guney E. Egea J. López M. G. Baumbach J. J. From Single Drug Targets to Synergistic Network Pharmacology in Ischemic Stroke Proceedings of the National Academy of Sciences 2019 116 7129 7136 10.1073/pnas.1820799116 PMC6452748 30894481 3 Wu X. Jiang R. Zhang M. Q. Li S. Network-Based Global Inference of Human Disease Genes Molecular Systems Biology 2008 4 1 11 10.1038/msb.2008.27 PMC2424293 18463613 4 Chandran U. Mehendale N. Patil S. Chaguturu R. Patwardhan B. Network Pharmacology Chapter 5: Innovative Approaches in Drug Discovery 2017 Elsevier Inc. 127 164 10.1016/B978-0-12-801814-9.00005-2 5 Liu B. Zhang J. Shao L. Yao J. Network Pharmacology Analysis and Molecular Docking to Unveil the Potential Mechanisms of San-Huang-Chai-Zhu Formula Treating Cholestasis PLoS One 2022 17 e0264398 10.1371/journal.pone.0264398 35196362 PMC8865668 6 Alamri M. A. Qamar M. T. Network Pharmacology Based Virtual Screening of Flavonoids From Dodonea angustifolia Saudi Pharmaceutical Journal 2023 31 101802 10.1016/j.jsps.2023.101802 37822694 PMC10563060 7 Li H. Zhao L. Zhang B. Jiang Y. Wang X. Guo Y. Liu H. Li S. Tong X. A. A Network Pharmacology Approach to Determine Active Compounds and Action Mechanisms of Ge-Gen-Qin-Lian Decoction for Treatment of Type 2 Diabetes Evidence-Based Complementary and Alternative Medicine 2014 2014 495840 10.1155/2014/495840 24527048 PMC3914348 8 Akoonjee A. Lukman H. Y. Ajao A. A. Uthman T. O. Sabiu S. A Network Pharmacology- and Molecular Dynamics Simulation-Based Bioprospection of Khaya grandifoliola Journal of Biomolecular Structure & Dynamics 2024 1 20 10.1080/07391102.2024.2446672 9 Maradesha T. Martiz R. M. Patil S. M. Prasad A. Babakr A. T. Silina E. Stupin V. Achar R. R. Ramu R. Integrated Network Pharmacology and Molecular Modeling Approach for the Discovery of Novel Potential MAPK3 Inhibitors From Whole Green Jackfruit Flour Targeting Obesity-Linked Diabetes Mellitus PLoS One 2023 18 e0280847 10.1371/journal.pone.0280847 36716329 PMC9886246 10 World Health Organization Factsheets. Diabetes 2021 https://www.who.int/news-room/fact-sheets/detail/diabetes 11 Farag H. F. M. Elrewany E. Abdel-Aziz B. F. Sultan E. A. Prevalence and Predictors of Undiagnosed Type 2 Diabetes and Pre-Diabetes Among Adult Egyptians: A Community-Based Survey BMC Public Health 2023 23 10.1186/s12889-023-15819-0 PMC10210310 37231362 12 American Diabetes Association (ADA) Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers Clinical Diabetes 2022 40 10 38 10.2337/cd22-as01 35221470 PMC8865785 13 Thakare V. Shende S. S. Shirure P. A. Swami O. C. Role of Conventional Oral Antidiabetic Drugs in Management of Type 2 Diabetes Mellitus International Journal of Research in Medical Sciences 2017 5 749 758 10.18203/2320-6012.ijrms20170619 14 Hung H. Y. Qian K. Morris-Natschke S. L. Hsu C. S. Lee K. H. Recent Discovery of Plant-Derived Anti-Diabetic Natural Products Natural Product Reports 2012 29 580 606 10.1039/c2np00074a 22491825 15 Di S. Han L. An X. Kong R. Gao Z. Yang Y. Tong X.  In Silico In Vivo Journal of Ethnopharmacology 2021 276 114180 10.1016/j.jep.2021.114180 33957209 16 Oh K. K. Adnan M. Cho D. H. Network Pharmacology of Bioactives From Sorghum Bicolor With Targets Related to Diabetes Mellitus PLoS One 2020 15 e0240873 10.1371/journal.pone.0240873 33382706 PMC7774932 17 Adnan M. Jeon B.-B. Chowdhury M. H. U. Oh K.-K. Das T. Chy M. N. U. Cho D.-H. Network Pharmacology Study to Reveal the Potentiality of a Methanol Extract of Caesalpinia sappan Life 2022 12 10.3390/life12020277 PMC8880704 35207564 18 Akoonjee A. Rampadarath A. Aruwa C. E. Ajiboye T. A. Ajao A. A. N. Sabiu S. Network Pharmacology-and Molecular Dynamics Simulation-Based Bioprospection of Aspalathus linearis Metabolites 2022 12 10.3390/metabo12111013 PMC9692680 36355096 19 Rampadarath A. Balogun F. O. Sabiu S. Insights Into the Mechanism of Action of Helianthus annuus Endocrine 2023 4 327 349 10.3390/endocrines4020026 20 Rampadaratha A. Aribisalaa J. O. Makunga N. P. Mazibuko-Mbejec S. Sabiu S. Molecular Bioprospection of Helianthus annuus South African Journal of Botany 2023 162 72 95 10.1016/j.sajb.2023.08.045 21 Omoruyi B. E. Bradley G. Afolayan A. J. Antioxidant, and Phytochemical Properties of Carpobrotus edulis BMC Complementary and Alternative Medicine 2012 12 10.1186/1472-6882-12-215 PMC3528461 23140206 22 Albert M. E. D’Antonio C. M. Schierenbeck K. A. Hybridization and Introgression in Carpobrotus spp American Journal of Botany 1997 84 896 904 10.2307/2446279 21708643 23 Wisura W. Glen H. F. The South African Species of Carpobrotus (Mesembryanthema–Aizoaceae) Contributions to the Bolus Herbarium 1993 15 76 107 24 Akinyede K. A. Ekpo O. E. Oguntibeju O. O. Ethnopharmacology, Therapeutic Properties and Nutritional Potentials of Carpobrotus edulis: A Comprehensive Review Scientia Pharmaceutica 2020 88 10.3390/scipharm88030039 25 Omoruyi B. E. Afolayan A. J. Bradley G. Chemical Composition Profiling and Antifungal Activity of the Essential Oil and Plant Extracts of <i>Mesembryanthemum edule</i> (L.) Bolus Leaves African Journal of Traditional, Complementary, and Alternative Medicines 2014 11 19 30 10.4314/ajtcam.v11i4.4 PMC4202392 25392576 26 Mulaudzi R. B. Aremu A. O. Rengasamy K. R. Adebayo S. A. McGaw L. J. Amoo S. O. Van Staden J. Du Plooy C. P. Antidiabetic, Anti-Inflammatory, Anticholinesterase and Cytotoxicity Determination of Two Carpobrotus Species South African Journal of Botany 2019 125 142 148 10.1016/j.sajb.2019.07.007 27 Hafsa J. Hammi K. M. Khedher M. R. B. Smach M. A. Charfeddine B. Limem K. Majdoub H. Inhibition of Protein Glycation, Antioxidant and Antiproliferative Activities of Carpobrotus edulis Biomedicine & Pharmacotherapy 2016 84 1496 1503 10.1016/j.biopha.2016.11.046 27876336 28 Sabiu S. Balogun F. O. Amoo S. O. Phenolics Profiling of Carpobrotus edulis Molecules 2021 26 10.3390/molecules26164867 PMC8401050 34443458 29 Daina A. Michielin O. Zoete V. SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules Scientific Reports 2017 7 10.1038/srep42717 PMC5335600 28256516 30 Piñero J. Ramírez-Anguita J. M. Saüch-Pitarch J. Ronzano F. Centeno E. Sanz F. Furlong L. I. The DisGeNET Knowledge Platform for Disease Genomics: 2019 Update Nucleic Acids Research 2019 48 D845 D855 10.1093/nar/gkz1021 PMC7145631 31680165 31 Shannon P. Markiel A. Ozier O. Baliga N. S. Wang J. T. Ramage D. Amin N. Schwikowski B. Ideker T. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks Genome Research 2003 13 2498 2504 10.1101/gr.1239303 14597658 PMC403769 32 Huang Z. Shi X. Li X. Zhang L. Wu P. Mao J. Xing R. Zhang N. Wang P. Network Pharmacology Approach to Uncover the Mechanism Governing the Effect of Simiao Powder on Knee Osteoarthritis BioMed Research International 2020 2020 6971503 10.1155/2020/6971503 33376732 PMC7738782 33 Zeng Z. Hu J. Jiang J. Xiao G. Yang R. Li S. Bi X. Network Pharmacology and Molecular Docking-Based Prediction of the Mechanism of Qianghuo Shengshi Decoction Against Rheumatoid Arthritis BioMed Research International 2021 2021 6623912 10.1155/2021/6623912 34527739 PMC8437630 34 Branden G. Sjogren T. Schnecke V. Xue Y. Structure-Based Ligand Design to Overcome CYP Inhibition in Drug Discovery Projects Drug Discovery Today 2014 19 905 911 10.1016/j.drudis.2014.03.012 24642031 35 Kim S. Thiessen P. A. Bolton E. E. Chen J. Fu G. Gindulyte A. Han L. He J. He S. Shoemaker B. A. Wang J. Yu B. Zhang J. Bryant S. H. PubChem Substance and Compound Databases Nucleic Acids Research 2016 44 D1202 D1213 10.1093/nar/gkv951 26400175 PMC4702940 36 Xin W. Zi-Yi W. Zheng J.-H. Shao L. TCM Network Pharmacology: A New Trend Towards Combining Computational, Experimental, and Clinical Approaches Chinese Journal of Natural Medicines 2021 19 1 11 33516447 10.1016/S1875-5364(21)60001-8 37 Nair P. C. Miners J. O. Molecular Dynamics Simulations: From Structure Function Relationships to Drug Discovery In Silico Pharmacology 2014 2 1 4 25516823 10.1186/s40203-014-0004-8 PMC4244305 38 Seifert E. OriginPro 9.1. Scientific Data Analysis and Graphing Software-Software Review Journal of Chemical Information and Modeling 2014 54 10.1021/ci500161d 24702057 39 Gonnet P. P-SHAKE: A Quadratically Convergent SHAKE in Journal of Computational Physics 2007 220 740 750 10.1016/j.jcp.2006.05.032 40 BIOVIA D. S. Discovery Studio, version 21.1.0 San Diego: Dassault Systèmes 2021 627 41 Noor F. Saleem M. H. Aslam M. F. Ahmad A. Aslam S. Construction of miRNA-mRNA Network for the Identification of Key Biological Markers and Their Associated Pathways in IgA Nephropathy by Employing the Integrated Bioinformatics Analysis Saudi Journal of Biological Sciences 2021 28 4938 4945 10.1016/j.sjbs.2021.06.079 34466069 PMC8381040 42 Pal S. K. Shukla Y. Herbal Medicine: Current Status and the Future Asian Pacific Journal of Cancer Prevention 2003 4 281 288 14728584 43 Rehman A. Ashfaq U. A. Shahid F. Noor F. Aslam S. The Screening of Phytochemicals Against NS5 Polymerase to Treat Zika Virus Infection: Integrated Computational Based Approach Combinatorial Chemistry & High Throughput Screening 2021 25 738 751 10.2174/1386207324666210712091920 34254908 44 Zhang R. Zhu X. Bai H. Ning K. Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment Frontiers in Pharmacology 2019 10 10.3389/fphar.2019.00123 PMC6393382 30846939 45 Pinzi L. Rastelli G. Molecular Docking: Shifting Paradigms in Drug Discovery International Journal of Molecular Sciences 2019 20 10.3390/ijms20184331 PMC6769923 31487867 46 Slominski B. Mysliwska J. Ryba-Stanislawowska M. Skrzypkowska M. Mysliwiec M. Estrogen Receptor α Molecular and Cellular Biochemistry 2018 437 153 161 10.1007/s11010-017-3103-0 28634856 PMC5752735 47 Bastos H. P. Tavares B. Pesquita C. Faria D. Couto F. M. Yu B. Hinchcliffe M. Application of Gene Ontology to Gene Identification In Silico Tools for Gene Discovery. Methods in Molecular Biology 2011 760 Humana Press 10.1007/978-1-61779-176-5_9 21779995 48 Krijnen P. A. Simsek S. Niessen H. W. Apoptosis in Diabetes Apoptosis 2009 14 1387 1388 10.1007/s10495-009-0419-6 19856207 PMC2773035 49 Gupta P. Taiyab A. Hassan M. I. Emerging Role of Protein Kinases in Diabetes Mellitus: From Mechanism to Therapy Advances in Protein Chemistry and Structural Biology 2021 124 10.1016/bs.apcsb.2020.11.001 33632470 50 Dittmer J. Nuclear Mechanisms Involved in Endocrine Resistance Frontiers in Oncology 2021 11 736597 10.3389/fonc.2021.736597 34604071 PMC8480308 51 Hevener A. L. Zhou Z. Moore T. M. Drew B. G. Ribas V. The Impact of ER α Molecular Metabolism 2018 15 20 34 10.1016/j.molmet.2018.06.013 30005878 PMC6066787 52 Meyer M. R. Clegg D. J. Prossnitz E. R. Barton M. Obesity, Insulin Resistance and Diabetes: Sex Differences and Role of Oestrogen Receptors Acta Physiologica 2011 203 259 269 10.1111/j.1748-1716.2010.02237.x 21281456 PMC3110567 53 Arámbul-Carrillo C. E. Ramos-Márquez M. E. Carrillo-Pérez M. C. Association Between Polymorphism in the AKT1 Gene and Type 2 Diabetes Mellitus in a Mexican Population Revista Mexicana de Endocrinología, Metabolismo & Nutrición 2015 2 167 170 54 Kumagai S. Koyama S. Nishikawa H. Antitumour Immunity Regulated by Aberrant ERBB Family Signalling Nature Reviews Cancer 2021 21 181 197 10.1038/s41568-020-00322-0 33462501 55 Boucher J. Tseng Y.-H. Kahn C. R. Insulin and Insulin-Like Growth Factor-1 Receptors Act as Ligand-Specific Amplitude Modulators of a Common Pathway Regulating Gene Transcription Journal of Biological Chemistry 2010 285 17235 17245 10.1074/jbc.M110.118620 20360006 PMC2878077 56 Chen Q. Jin M. Yang F. Zhu J. Xiao Q. Zhang L. Matrix Metalloproteinases: Inflammatory Regulators of Cell Behaviors in Vascular Formation and Remodeling Mediators of Inflammation 2013 2013 928315 10.1155/2013/928315 23840100 PMC3694547 57 Sato H. Nagashima K. Ogura M. Sato Y. Tahara Y. Ogura K. Yamano G. Sugizaki K. Fujita N. Tatsuoka H. Usui R. Mukai E. Fujimoto S. Inagaki N. SRC Regulates Insulin Secretion and Glucose Metabolism by Influencing Subcellular Localization of Glucokinase in Pancreatic β Journal of Diabetes Investigation 2016 7 171 178 10.1111/jdi.12407 27042268 PMC4773676 58 Lv X. Xu Z. Xu G. Li H. Wang C. Chen J. Sun J. Investigation of the Active Components and Mechanisms of Schisandra chinensis in the Treatment of Asthma Based on a Network Pharmacology Approach and Experimental Validation Food & Function 2020 11 3032 3042 10.1039/D0FO00087F 32186565 59 Zhang Y. Shi G. Luo Z. Wang J. Wu S. Zhang X. Zhao Y. Activity Components From Gynostemma pentaphyllum Molecules 2021 26 10.3390/molecules26103006 PMC8158484 34070150 60 Lukman H. Y. Kuo Y. Owolabi M. S. Lawal B. Chen L. C. Ajenifujah O. T. Fadaka A. O. Olawale F. Onikanni S. A. Sani S. De Waard M. Fouad D. Batiha G. E. Sabiu S. Wu A. T. H. Huang H. S. Evaluation of Terpenes Rich Hura crepitans Biomedicine & Pharmacotherapy 2024 179 117308 10.1016/j.biopha.2024.117308 39180791 61 Kumi R. O. Soremekun O. S. Issahaku A. R. Fisayo C. A. Olotu A. Soliman M. E. S. Exploring the Ring Potential of 2,4-Diaminopyrimidine Derivatives Towards the Identification of Novel Caspase-1 Inhibitors in Alzheimer’s Disease Therapy Journal of Molecular Modeling 2020 26 10.1007/s00894-020-4319-6 32130533 62 Mpofana N. Peter C. Lukman H. Y. Makgobole M. U. Dlova N. C. Gqaleni N. Hussein A. Sabiu S. Mechanisms of Selected Cassipourea Metabolites for Melasma Treatment: Network Pharmacology and Molecular Dynamics Study F1000Research 2024 13 10.12688/f1000research.153996.1 63 Sulyman A. O. Aliyu O. M. Ajani E. O. Abdulkareem Y. F. Afe I. A. Abdulyakeen F. O. Lukman H. Y. Sabiu S. Singh K. Naidoo K. Mechanisms of L-Citrulline on Phosphodiesterase 5 in Erectile Dysfunction Intervention Scientific African 2025 27 e02572 10.1016/j.sciaf.2025.e02572 64 Sindhu T. Srinivasan P. Exploring the Binding Properties of Agonists Interacting With Human TGR5 Using Structural Modeling, Molecular Docking and Dynamics Simulations RSC Advances 2015 5 14202 14213 10.1039/C4RA16617E 65 Hubbard R. E. Haider M. K. Hydrogen Bonds in Proteins: Role and Strength 2010 eLS John Wiley & Sons, Ltd. 66 Abdolmaleki A. Shiri F. Ghasemi J. B. Use of molecular docking as a decision-making tool in drug discovery Molecular docking for computer-aided drug design 2021 Academic Press 67 Gupta A. Sharma M. Sharma J. A Role of Insulin in Different Types of Diabetes International Journal of Current Microbiology and Applied Sciences 2015 4 58 77 68 AL-Ishaq R. K. Abotaleb M. Kubatka P. Kajo K. Büsselberg D. Flavonoids and Their Anti-Diabetic Effects: Cellular Mechanisms and Effects to Improve Blood Sugar Levels Biomolecules 2019 9 10.3390/biom9090430 PMC6769509 31480505 69 Amor A. J. Gómez-Guerrero C. Ortega E. Sala-Vila A. Lázaro I. Ellagic Acid as a Tool to Limit the Diabetes Burden: Updated Evidence Antioxidants 2020 9 10.3390/antiox9121226 PMC7761821 33287432 70 Niisato N. Marunaka Y. Therapeutic Potential of Multifunctional Myricetin for Treatment of Type 2 Diabetes Mellitus Frontiers in Nutrition 2023 10 1175660 10.3389/fnut.2023.1175660 37305094 PMC10251146 71 Abdelmageed M. E. Shehatou G. S. G. Suddek G. M. Salem H. A. Protocatechuic Acid Improves Hepatic Insulin Resistance and Restores Vascular Oxidative Status in Type-2 Diabetic Rats Environmental Toxicology and Pharmacology 2021 83 103577 10.1016/j.etap.2020.103577 33383195 72 Wen L. Wu D. Tan X. Zhong M. Xing J. Li W. Li D. Cao F. The Role of Catechins in Regulating Diabetes: An Update Review Nutrients 2022 14 10.3390/nu14214681 PMC9654920 36364943 ",
  "metadata": {
    "Title of this paper": "The Role of Catechins in Regulating Diabetes: An Update Review",
    "Journal it was published in:": "BioMed Research International",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12459310/"
  }
}